Walleye Capital
APLS

Walleye Capital’s Apellis Pharmaceuticals APLS Stock Holding History

Walleye Capital’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.62M Buy
40,200
+35,400
+738% +$763K 0.01% 1640
2025
Q4 		$121K Sell
4,800
-8,000
-63% -$188K ﹤0.01% 3796
2025
Q3 		$290K Sell
12,800
-7,100
-36% -$166K ﹤0.01% 3033
2025
Q2 		$344K Buy
19,900
+10,400
+109% +$193K ﹤0.01% 2946
2025
Q1 		$208K Buy
9,500
+4,700
+98% +$130K ﹤0.01% 3232
2024
Q4 		$153K Buy
+4,800
New +$144K ﹤0.01% 3919
2024
Q3 		– Sell
-12,800
Closed -$491K – 5240
2024
Q2 		$491K Sell
12,800
-43,100
-77% -$1.95M ﹤0.01% 3536
2024
Q1 		$3.29M Buy
55,900
+45,900
+459% +$2.93M 0.01% 1622
2023
Q4 		$599K Sell
10,000
-30,700
-75% -$1.56M ﹤0.01% 2800
2023
Q3 		$1.55M Buy
40,700
+27,200
+201% +$1.19M ﹤0.01% 1921
2023
Q2 		$1.23M Buy
13,500
+7,400
+121% +$638K ﹤0.01% 1679
2023
Q1 		$402K Sell
6,100
-12,200
-67% -$704K 0.01% 1883
2022
Q4 		$946K Buy
18,300
+3,600
+24% +$191K 0.02% 1036
2022
Q3 		$1M Buy
+14,700
New +$870K 0.02% 971
2020
Q2 		– Sell
-9,500
Closed -$255K – 608
2020
Q1 		$255K Buy
+9,500
New +$337K 0.06% 377

Other funds holding APLS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Walleye Capital's APLS Position: Q1 2026 in Review

Walleye Capital reduced its Apellis Pharmaceuticals (APLS) stake by 17% in Q1 2026, selling an estimated $14.3K and leaving 3,290 shares worth $132K. The position accounts for ﹤0.01% of the portfolio, ranked #3548.

Walleye Capital first reported a position in APLS in Q4 2021 and has held it in 15 quarters since. The position peaked at $12.6M in Q4 2024. 321 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Walleye Capital held 3,290 shares of Apellis Pharmaceuticals worth $132K as of Q1 2026.
  • Walleye Capital sold 665 Apellis Pharmaceuticals shares in Q1 2026, an estimated $14.3K.
  • Apellis Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3548 holding.
  • Walleye Capital first reported a position in Apellis Pharmaceuticals in Q4 2021 and has held it in 15 quarters since.
  • Walleye Capital's Apellis Pharmaceuticals position peaked at $12.6M in Q4 2024.
  • 321 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.